Novartis

Explore the latest insights on Novartis and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Novartis’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Novartis, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Novartis please access flcube.com

SynRx Therapeutics' SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status
CompanyDrug

SynRx Therapeutics’ SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status

SynRx Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to SYN818, the company's proprietary Polθ (DNA polymerase theta) inhibitor, in combination with…

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Novartis' Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism
CompanyDrug

Novartis’ Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease
CompanyDeals

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation
CompanyDeals

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation

Novartis' Cosentyx Wins Positive CHMP Opinion for Polymyalgia Rheumatica – IL‑17A Blockade Poised to Enter Steroid-Dependent Rheumatology
CompanyDrug

Novartis’ Cosentyx Wins Positive CHMP Opinion for Polymyalgia Rheumatica – IL‑17A Blockade Poised to Enter Steroid-Dependent Rheumatology

Novartis Exercises Exclusive Option to Acquire Global Rights to Sironax Brain Delivery Platform – USD 125 Million Transaction Targets Blood‑Brain Barrier Breakthrough for CNS Diseases
CompanyDeals

Novartis Exercises Exclusive Option to Acquire Sironax Brain Delivery Platform in USD 125 Million Transaction

CompanyDrug

Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis

NMPA Approves Novartis' Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
CompanyDrug

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

CompanyLegal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Show More